Literature DB >> 16375256

Heterogeneity of recombinant antibodies: linking structure to function.

R J Harris1.   

Abstract

Structural heterogeneity of recombinant IgG1 antibodies derives from variations in conserved as well as unique structural features. Common sources of heterogeneity include Fc glycosylation, partial heavy chain C-terminal Lys processing, Fc methionine oxidation, hinge-region cleavage, and the glycation of Lys residues. Aspartate residues that are isomerized to iso-aspartate were detected by cation exchange or hydrophobic interaction chromatography for trastuzumab and omalizumab, respectively. Unpaired cysteines were detected in omalizumab using Ellman's reagent, with the thiol-containing Fab resolved using hydrophobic interaction chromatography after papain digestion. Structural variations that cause chromatographic resolution may indicate the presence of a form with reduced potency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16375256

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  44 in total

1.  Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media.

Authors:  Timothy Kaschak; Daniel Boyd; Franklin Lu; Gayle Derfus; Brian Kluck; Bartek Nogal; Craig Emery; Christie Summers; Kai Zheng; Robert Bayer; Ashraf Amanullah; Boxu Yan
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates.

Authors:  Mauro Acchione; Hyewon Kwon; Claudia M Jochheim; William M Atkins
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 3.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

4.  Modifications of therapeutic proteins: challenges and prospects.

Authors:  Nigel Jenkins
Journal:  Cytotechnology       Date:  2007-05-25       Impact factor: 2.058

5.  A platform for characterizing therapeutic monoclonal antibody breakdown products by 2D chromatography and top-down mass spectrometry.

Authors:  Matthew T Mazur; Richard S Seipert; David Mahon; Qinwei Zhou; Tun Liu
Journal:  AAPS J       Date:  2012-05-12       Impact factor: 4.009

6.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

Review 7.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

8.  Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody.

Authors:  Douglas S Rehder; Chris J Wisniewski; Denfeng Liu; Diya Ren; Dell Farnan; Matthew R Schenauer
Journal:  MAbs       Date:  2018-11-07       Impact factor: 5.857

Review 9.  Assessing monoclonal antibody product quality attribute criticality through clinical studies.

Authors:  Andrew M Goetze; Matthew R Schenauer; Gregory C Flynn
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

10.  Glycine to glutamic acid misincorporation observed in a recombinant protein expressed by Escherichia coli cells.

Authors:  Yunping Huang; Brian O'Mara; Matthew Conover; Richard Ludwig; Jinmei Fu; Li Tao; Zheng Jian Li; Siegfried Rieble; Michael J Grace; Reb J Russell
Journal:  Protein Sci       Date:  2012-03-16       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.